A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
← catalyst calendarNCT06641466 · readout in 102 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
723estimated
Sites
123
Countries
Argentina, Canada, China +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-11 | actual | When the study began enrolling |
| Primary completion | 2026-11-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Menstrual Migraine
Interventions
- Drug: Rimegepant
- Drug: Placebo Comparator
- Drug: Standard of Care
- Drug: Rimegepant
Primary outcome
what the primary-completion date above is the date OFMean change from the Observation Period in number of migraine days per 5-day perimenstrual period across each cycle of the Double-Blind Treatment Phase
measured 5 months (5 menstrual cycles)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed